NCT05254535

Brief Summary

This pragmatic clinical trial is being conducted to test the effectiveness of I-SITE (Implementation for Sustained Impact in Teleophthalmology), an implementation program to sustain increased diabetic eye screening rates using teleophthalmology in rural, multi-payer health systems. Up to 10 rural health systems providing teleophthalmology to 10,000 patients with diabetes and 100 clinical care personnel participating in the I-SITE intervention will be enrolled for up to 48 months.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
32mo left

Started Mar 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress55%
Mar 2023Dec 2028

First Submitted

Initial submission to the registry

February 23, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 24, 2022

Completed
1.1 years until next milestone

Study Start

First participant enrolled

March 28, 2023

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

Expected
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2028

Last Updated

May 15, 2026

Status Verified

May 1, 2026

Enrollment Period

4.4 years

First QC Date

February 23, 2022

Last Update Submit

May 12, 2026

Conditions

Keywords

Rural HealthScreeningTeleophthalmologyTelemedicinePreventative Medicine

Outcome Measures

Primary Outcomes (1)

  • Proportion of Patients Who Complete Annual Diabetic Eye Screening

    Comparison of proportion of patients with diabetes adherent with yearly diabetic eye screening guidelines (i.e., "screening rates") between baseline and 24 months following initiation of I-SITE implementation at each site.

    24 months

Secondary Outcomes (4)

  • Change in Proportion of Patients Who Complete Annual Diabetic Eye Screening

    baseline, 12 months, 36 months, 48 months

  • Change in follow-up rates for in-person eye care among screen positive patients

    baseline, 12 months, 36 months, 48 months

  • Identification of workflow strategies, organizational factors, and implementation components that distinguish between health systems with high and low teleophthalmology use

    up to 13 months

  • Mean Implementation Cost

    up to 48 months

Study Arms (1)

Intervention

OTHER

Up to 10 rural health systems will be participating in I-SITE implementation with cluster-randomization of the order of initiation for the intervention. All sites will receive usual care teleophthalmology prior to I-SITE implementation.

Other: I-SITE

Interventions

I-SITEOTHER

I-SITE includes coaching facilitation, technical assistance, and an online toolkit to allow primary care clinics to tailor the integration of teleophthalmology into their daily workflows based on each clinic's unique needs and resources. The program includes a series of coaching sessions between a skilled practice facilitator and clinical personnel at each health system.

Also known as: Implementation for Sustained Impact in Teleophthalmology
Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Health system serves rural patients as defined as those patients living in counties considered rural by the federal Office of Management and Budget (OMB)
  • Health system has an active clinical teleophthalmology program providing diabetic eye screening in primary care prior to study randomization
  • Health system agrees to share de-identified patient data at the requested time intervals

You may not qualify if:

  • Health system does not serve a rural patient population
  • Health system has a diabetic eye screening rate of greater than 50% (e.g., above the national average) as it may limit the ability to measure improvement from I-SITE

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UW School of Medicine and Public Health

Madison, Wisconsin, 53792, United States

Location

Related Publications (2)

  • Liu Y, Carlson JN, Torres Diaz A, Lock LJ, Zupan NJ, Molfenter TD, Mahoney JE, Palta M, Boss D, Bjelland TD, Smith MA. Sustaining Gains in Diabetic Eye Screening: Outcomes from a Stakeholder-Based Implementation Program for Teleophthalmology in Primary Care. Telemed J E Health. 2021 Sep;27(9):1021-1028. doi: 10.1089/tmj.2020.0270. Epub 2020 Nov 19.

    PMID: 33216697BACKGROUND
  • Torres Diaz A, Lock LJ, Molfenter TD, Mahoney JE, Boss D, Bjelland TD, Liu Y. Implementation for Sustained Impact in Teleophthalmology (I-SITE): applying the NIATx Model for tailored implementation of diabetic retinopathy screening in primary care. Implement Sci Commun. 2021 Jul 6;2(1):74. doi: 10.1186/s43058-021-00175-0.

    PMID: 34229748BACKGROUND

Related Links

MeSH Terms

Conditions

Diabetic Retinopathy

Interventions

Deoxyribonucleases, Type I Site-Specific

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System Diseases

Intervention Hierarchy (Ancestors)

DNA Restriction EnzymesDNA Restriction-Modification EnzymesEnzymesEnzymes and CoenzymesEndodeoxyribonucleasesDeoxyribonucleasesEsterasesHydrolasesEndonucleases

Study Officials

  • Yao Liu, MD, MS

    University of Wisconsin, Madison

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Model Details: Cluster-randomized trial with a stepped-wedge initiation of the intervention at each site
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 23, 2022

First Posted

February 24, 2022

Study Start

March 28, 2023

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

December 31, 2028

Last Updated

May 15, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will share

Data from this study may be requested from other researchers up to 7 years after the completion of the primary outcome by contacting Dr. Yao Liu, the Principal Investigator of this study.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
up to 7 years after the completion of the primary outcome

Locations